ATE481108T1 - Verwendung von bioadhaesiven und adjuvantien für die mukosale anwendung von antigenen - Google Patents
Verwendung von bioadhaesiven und adjuvantien für die mukosale anwendung von antigenenInfo
- Publication number
- ATE481108T1 ATE481108T1 AT99930126T AT99930126T ATE481108T1 AT E481108 T1 ATE481108 T1 AT E481108T1 AT 99930126 T AT99930126 T AT 99930126T AT 99930126 T AT99930126 T AT 99930126T AT E481108 T1 ATE481108 T1 AT E481108T1
- Authority
- AT
- Austria
- Prior art keywords
- adjuvants
- antigens
- bioadhaesives
- mucosal application
- compositions
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/543—Mucosal route intranasal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55544—Bacterial toxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12217299P | 1999-02-26 | 1999-02-26 | |
PCT/US1999/011906 WO2000050078A1 (en) | 1999-02-26 | 1999-05-28 | Use of bioadhesives and adjuvants for the mucosal delivery of antigens |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE481108T1 true ATE481108T1 (de) | 2010-10-15 |
Family
ID=22401126
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT99930126T ATE481108T1 (de) | 1999-02-26 | 1999-05-28 | Verwendung von bioadhaesiven und adjuvantien für die mukosale anwendung von antigenen |
Country Status (10)
Country | Link |
---|---|
US (1) | US20050281843A1 (de) |
EP (2) | EP1154793B1 (de) |
JP (2) | JP2002537355A (de) |
AT (1) | ATE481108T1 (de) |
AU (1) | AU4673099A (de) |
CA (1) | CA2366688A1 (de) |
DE (1) | DE69942774D1 (de) |
ES (1) | ES2350306T3 (de) |
PT (1) | PT1154793E (de) |
WO (1) | WO2000050078A1 (de) |
Families Citing this family (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9706957D0 (en) | 1997-04-05 | 1997-05-21 | Smithkline Beecham Plc | Formulation |
GB9820525D0 (en) | 1998-09-21 | 1998-11-11 | Allergy Therapeutics Ltd | Formulation |
GB0000891D0 (en) | 2000-01-14 | 2000-03-08 | Allergy Therapeutics Ltd | Formulation |
AUPQ797700A0 (en) | 2000-06-06 | 2000-06-29 | Austin Research Institute, The | Vaccine |
WO2008037033A1 (en) * | 2006-09-29 | 2008-04-03 | The Macfarlane Burnet Institute For Medical Research And Public Health Limited | Flu vaccine admixture of mannan and flu antigen |
EP1363663B1 (de) * | 2001-01-12 | 2011-03-02 | Novartis Vaccines and Diagnostics, Inc. | Nukleinsäure mukosale immunisierung |
WO2002064113A1 (en) * | 2001-02-15 | 2002-08-22 | Access Pharmaceuticals, Inc. | Liquid formulations for the prevention and treatment of mucosal diseases and disorders |
US7544348B2 (en) | 2001-02-15 | 2009-06-09 | Access Pharmaceuticals, Inc. | Liquid formulations for the prevention and treatment of mucosal diseases and disorders |
ITMI20010571A1 (it) * | 2001-03-19 | 2002-09-19 | Grisotech S A | Vaccini assorbibili per via trans-mucosale |
US6585997B2 (en) | 2001-08-16 | 2003-07-01 | Access Pharmaceuticals, Inc. | Mucoadhesive erodible drug delivery device for controlled administration of pharmaceuticals and other active compounds |
AU2003276679A1 (en) | 2002-06-13 | 2003-12-31 | Chiron Corporation | Vectors for expression of hml-2 polypeptides |
GB0218921D0 (en) * | 2002-08-14 | 2002-09-25 | Glaxosmithkline Biolog Sa | Novel vaccine |
GB0220194D0 (en) | 2002-08-30 | 2002-10-09 | Chiron Spa | Improved vesicles |
GB0308198D0 (en) | 2003-04-09 | 2003-05-14 | Chiron Srl | ADP-ribosylating bacterial toxin |
US20050123550A1 (en) * | 2003-05-12 | 2005-06-09 | Laurent Philippe E. | Molecules enhancing dermal delivery of influenza vaccines |
US7588774B2 (en) | 2003-05-12 | 2009-09-15 | Becton, Dickinson And Company | Molecules enhancing dermal delivery of influenza vaccines |
ES2237298B1 (es) | 2003-07-16 | 2006-11-01 | Italfarmaco, S.A. | Formulaciones mucoadhesivas semisolidas. |
CN101355960A (zh) | 2005-10-18 | 2009-01-28 | 诺华疫苗和诊断公司 | 使用α病毒复制子颗粒进行粘膜和全身免疫 |
CA2647942A1 (en) | 2006-03-31 | 2007-11-08 | Novartis Ag | Combined mucosal and parenteral immunization against hiv |
US9839685B2 (en) * | 2006-04-13 | 2017-12-12 | The Regents Of The University Of Michigan | Methods of inducing human immunodeficiency virus-specific immune responses in a host comprising nasally administering compositions comprising a naonemulsion and recombinant GP120 immunogen |
US10138279B2 (en) | 2006-04-13 | 2018-11-27 | Regents Of The University Of Michigan | Compositions and methods for Bacillus anthracis vaccination |
EP2152304B1 (de) | 2007-05-02 | 2018-08-22 | The Regents of the University of Michigan | Therapeutische zusammensetzungen in nanoemulsionsform und anwendungsverfahren dafür |
WO2010033274A2 (en) * | 2008-05-23 | 2010-03-25 | The Regents Of The University Of Michigan | Nanoemulsion adjuvants |
WO2009143524A2 (en) | 2008-05-23 | 2009-11-26 | The Regents Of The University Of Michigan | Nanoemulsion vaccines |
ES2344673B1 (es) | 2008-08-07 | 2011-05-03 | Italfarmaco, S.A. | Uso de estriol en la preparacion de una formulacion farmaceutica parael tratamiento de atrofia vaginal en mujeres con riesgo de potologiatumoral. |
CN102223876A (zh) | 2008-09-26 | 2011-10-19 | 纳米生物公司 | 纳米乳剂治疗性组合物及其使用方法 |
EP2376089B1 (de) | 2008-11-17 | 2018-03-14 | The Regents of the University of Michigan | Krebsvakzine-zusammensetzungen und anwendungsverfahren dafür |
ES2344675B1 (es) | 2008-12-19 | 2011-04-28 | Italfarmaco, S.A. | Uso de estriol en la preparacion de una formulacion farrmaceutica para el tratamiento de atrofia vaginal en mujeres con riesgo de patologiacardiovascular. |
EP2413961B1 (de) | 2009-03-31 | 2016-08-17 | Japan As Represented By The Director-General Of National Institute Of Infectious Diseases | Verfahren zur influenza-prophylaxe mit einem impfstoff zur intranasalen verabreichung |
WO2010132833A1 (en) | 2009-05-14 | 2010-11-18 | The Regents Of The University Of Michigan | Streptococcus vaccine compositions and methods of using the same |
EP2442827B1 (de) * | 2009-06-16 | 2016-01-06 | The Regents of the University of Michigan | Nanoemulsionsimpfstoffe |
EP2515661A4 (de) * | 2009-12-23 | 2013-11-13 | Vaxgene Corp | Immunschutz durch orale verabreichung von minikapseln mit rekombinantem lactococcus lactis |
WO2011116262A2 (en) * | 2010-03-19 | 2011-09-22 | The Regents Of The University Of Michigan | Compositions and methods for diagnosing and treating urinary tract infections |
US8658603B2 (en) | 2010-06-16 | 2014-02-25 | The Regents Of The University Of Michigan | Compositions and methods for inducing an immune response |
US9433644B2 (en) | 2013-07-25 | 2016-09-06 | Rutgilli Pharmaceuticals, Llc | Formulations and methods for treating oral inflammation, injury, or pain |
WO2015063611A2 (en) | 2013-11-01 | 2015-05-07 | University Of Oslo | Albumin variants and uses thereof |
DK3069138T3 (en) | 2013-11-15 | 2019-04-08 | Univ Oslo Hf | CTL PEPTID EPITOPES AND ANTIGEN-SPECIFIC T-CELLS, METHODS OF RECOGNITION THEREOF, AND APPLICATIONS THEREOF |
JP7158853B2 (ja) | 2014-10-10 | 2022-10-24 | ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン | 対象における食物アレルギーまたは呼吸器アレルギーを処置するための、かつ上記対象の鼻腔内に投与するための免疫原性組成物 |
WO2016141320A2 (en) | 2015-03-05 | 2016-09-09 | Northwestern University | Non-neuroinvasive viruses and uses thereof |
TW201709926A (zh) * | 2015-04-23 | 2017-03-16 | 賽諾菲公司 | 用於舌下投藥之吡喃葡萄糖基脂a及過敏原調配物 |
TN2018000301A1 (en) | 2016-03-14 | 2020-01-16 | Univ Oslo | Engineered immunoglobulins with altered fcrn binding |
WO2017158421A1 (en) | 2016-03-14 | 2017-09-21 | University Of Oslo | Anti-viral engineered immunoglobulins |
US11173207B2 (en) | 2016-05-19 | 2021-11-16 | The Regents Of The University Of Michigan | Adjuvant compositions |
WO2017221072A2 (en) | 2016-06-21 | 2017-12-28 | University Of Oslo | Hla binding vaccine moieties and uses thereof |
WO2018096396A1 (en) | 2016-11-22 | 2018-05-31 | University Of Oslo | Albumin variants and uses thereof |
NL2018155B1 (en) | 2017-01-11 | 2018-07-25 | Intervet Int Bv | Oral vaccine against ruminant respiratory disease |
EP3678699A1 (de) | 2017-09-07 | 2020-07-15 | University Of Oslo | Impfstoffmoleküle |
US20220118076A1 (en) | 2017-09-07 | 2022-04-21 | University Of Oslo | Vaccine molecules |
KR102092258B1 (ko) * | 2018-05-23 | 2020-03-23 | 가톨릭대학교 산학협력단 | 광감각제가 접합된 고분자를 유효성분으로 포함하는 면역증강제, 바이러스 감염 또는 암 예방 또는 치료용 백신 조성물 |
WO2022207793A1 (en) | 2021-03-31 | 2022-10-06 | Vib Vzw | Vaccine compositions for trypanosomatids |
GB202205231D0 (en) * | 2022-04-09 | 2022-05-25 | Nasaleze Patents Ltd | Vaccine compositions |
Family Cites Families (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS523342B2 (de) | 1972-01-26 | 1977-01-27 | ||
US4491632A (en) | 1979-10-22 | 1985-01-01 | The Massachusetts General Hospital | Process for producing antibodies to hepatitis virus and cell lines therefor |
US4444887A (en) | 1979-12-10 | 1984-04-24 | Sloan-Kettering Institute | Process for making human antibody producing B-lymphocytes |
EP0043718B1 (de) | 1980-07-07 | 1984-11-28 | National Research Development Corporation | Zellinien |
US4341761A (en) | 1980-07-25 | 1982-07-27 | E. I. Du Pont De Nemours And Company | Antibodies to immunogenic peptides and their use to purify human fibroblast interferon |
US4466917A (en) | 1981-02-12 | 1984-08-21 | New York University | Malaria vaccine |
US4493890A (en) | 1981-03-23 | 1985-01-15 | Miles Laboratories, Inc. | Activated apoglucose oxidase and its use in specific binding assays |
JPS5873993U (ja) | 1981-11-12 | 1983-05-19 | 三菱電機株式会社 | 2気筒回転式圧縮機 |
US4399121A (en) | 1981-11-04 | 1983-08-16 | Miles Laboratories, Inc. | Iodothyronine immunogens and antibodies |
US4427783A (en) | 1981-12-14 | 1984-01-24 | Hoffmann-La Roche Inc. | Immunoassay of thymosin α1 |
US5324513A (en) | 1984-03-07 | 1994-06-28 | Institut Pasteur | Composition useful for the fabrication of vaccines |
US5171568A (en) | 1984-04-06 | 1992-12-15 | Chiron Corporation | Recombinant herpes simplex gb-gd vaccine |
US5098704A (en) | 1984-06-18 | 1992-03-24 | Chiron Corporation | Hepatitis surface antigen particle vaccine |
US4722840A (en) | 1984-09-12 | 1988-02-02 | Chiron Corporation | Hybrid particle immunogens |
DE3788902T3 (de) | 1986-06-17 | 2004-11-25 | Chiron Corp. (N.D.Ges.D. Staates Delaware), Emeryville | Hepatitis-Delta-Diagnostika und Impfstoffe, ihre Herstellung und Verwendung. |
US4944942A (en) * | 1987-08-27 | 1990-07-31 | Mobay Corporation | Intranasal vaccination of horses with inactivated microorganisms or antigenic material |
CN1074422C (zh) | 1987-11-18 | 2001-11-07 | 希龙股份有限公司 | 制备含有hcv表位的分离多肽的方法 |
HUT54896A (en) | 1989-03-17 | 1991-04-29 | Chiron Corp | Process for producing aquous diagnosticum and vaccine of nanbv |
DK0398748T3 (da) | 1989-05-18 | 2002-03-18 | Chiron Corp | NANBV-diagnostika: polynukleotider anvendelige til screening for hepatitis C virus |
JPH0832638B2 (ja) | 1989-05-25 | 1996-03-29 | カイロン コーポレイション | サブミクロン油滴乳剤を含んで成るアジュバント製剤 |
US5707644A (en) * | 1989-11-04 | 1998-01-13 | Danbiosyst Uk Limited | Small particle compositions for intranasal drug delivery |
IL101715A (en) | 1991-05-02 | 2005-06-19 | Amgen Inc | Recombinant dna-derived cholera toxin subunit analogs |
IT1247472B (it) | 1991-05-31 | 1994-12-17 | Fidia Spa | Processo per la preparazione di microsfere contenenti componenti biologicamente attivi. |
IT1253009B (it) | 1991-12-31 | 1995-07-10 | Sclavo Ricerca S R L | Mutanti immunogenici detossificati della tossina colerica e della tossina lt, loro preparazione ed uso per la preparazione di vaccini |
CN1120310A (zh) * | 1993-03-11 | 1996-04-10 | 塞科雷泰克公司 | 在粘膜表面转运免疫原的聚合粘膜粘合剂 |
GB9310412D0 (en) * | 1993-05-20 | 1993-07-07 | Danbiosyst Uk | Nasal nicotine system |
AU5543294A (en) * | 1993-10-29 | 1995-05-22 | Pharmos Corp. | Submicron emulsions as vaccine adjuvants |
GB9326174D0 (en) * | 1993-12-22 | 1994-02-23 | Biocine Sclavo | Mucosal adjuvant |
EP0817620B1 (de) | 1995-03-28 | 2002-01-30 | Fidia Advanced Biopolymers, S.R.L. | Nanosphären mit einem biokompatiblen polysaccharid |
US6818222B1 (en) * | 1997-03-21 | 2004-11-16 | Chiron Corporation | Detoxified mutants of bacterial ADP-ribosylating toxins as parenteral adjuvants |
WO2011130539A2 (en) | 2010-04-14 | 2011-10-20 | Northwestern University | Liquid cast biodegradable arterial stent |
-
1999
- 1999-05-28 EP EP99930126A patent/EP1154793B1/de not_active Expired - Lifetime
- 1999-05-28 EP EP10176376A patent/EP2275133A1/de not_active Withdrawn
- 1999-05-28 PT PT99930126T patent/PT1154793E/pt unknown
- 1999-05-28 JP JP2000600688A patent/JP2002537355A/ja not_active Withdrawn
- 1999-05-28 ES ES99930126T patent/ES2350306T3/es not_active Expired - Lifetime
- 1999-05-28 WO PCT/US1999/011906 patent/WO2000050078A1/en active Application Filing
- 1999-05-28 DE DE69942774T patent/DE69942774D1/de not_active Expired - Lifetime
- 1999-05-28 AT AT99930126T patent/ATE481108T1/de active
- 1999-05-28 CA CA002366688A patent/CA2366688A1/en not_active Abandoned
- 1999-05-28 AU AU46730/99A patent/AU4673099A/en not_active Abandoned
-
2005
- 2005-02-25 US US11/066,120 patent/US20050281843A1/en not_active Abandoned
-
2010
- 2010-10-15 JP JP2010233094A patent/JP2011006495A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
JP2011006495A (ja) | 2011-01-13 |
EP2275133A1 (de) | 2011-01-19 |
WO2000050078A1 (en) | 2000-08-31 |
EP1154793B1 (de) | 2010-09-15 |
US20050281843A1 (en) | 2005-12-22 |
EP1154793A1 (de) | 2001-11-21 |
PT1154793E (pt) | 2010-12-21 |
JP2002537355A (ja) | 2002-11-05 |
CA2366688A1 (en) | 2000-08-31 |
ES2350306T3 (es) | 2011-01-20 |
DE69942774D1 (de) | 2010-10-28 |
AU4673099A (en) | 2000-09-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE481108T1 (de) | Verwendung von bioadhaesiven und adjuvantien für die mukosale anwendung von antigenen | |
AU2002343557A1 (en) | Substituted aryl 1,4-pyrazine derivatives | |
DE69916581D1 (de) | Eine universelle immunmodulatorische cytokin-expressierende zelllinie in wartestelling. entsprechende zusammensetzungen und methoden ihrer herstellung und verwendungen | |
IL149459A0 (en) | Recombinant gelatins | |
ATE378403T1 (de) | Transchromosomale transgen-nagetiere zur herstellung von humänen antikörpern | |
CY1112862T1 (el) | Θραυσματα μονοσθενους αντισωματος χρησιμα ως θεραπευτικα | |
MY139523A (en) | Ziprasidone composition and synthetic controls | |
EG23427A (en) | Cultivated agarwood. | |
DE60236600D1 (de) | Substituierte 1h-dihydropyrazole, ihre herstellung und verwendung | |
CY1105963T1 (el) | Συνθεσεις καψομepιδιακου εμβολιου του ιου του θηλωματος και μεθοδοι χρησης | |
ATE407987T1 (de) | Neue mesogene, verfahren zu deren herstellung und verwendung | |
WO2003104425A3 (en) | NEW STABLE ANTI-CD22 ANTIBODIES | |
CY1106682T1 (el) | Ενωση λακταμης | |
ATE529401T1 (de) | Aminocyclohexylether-verbindungen und deren verwendung | |
DE60227718D1 (de) | Verwendung von 2-Fuoro-3-Ketoestern zur Herstellung von 3-Fuoro-6,7,8,9-tetrahydro-4H-pyrimidoÄ1,2-aÜpyrimidin-4-onen | |
ATE551069T1 (de) | Mucin-fusionspolypeptid-vakzine, zusammensetzungen und ihre verwendung | |
DE60137607D1 (de) | Substituierte cyclohexene | |
EP2292666A3 (de) | Neoplasma-spezifische Antikörper und deren Verwendungen | |
ATE285250T1 (de) | Verwendung von polymeren der hyaluronsäure zur mukosalen freigabe von impfstoffen und adjuvantien | |
MXPA05009428A (es) | Composiciones y metodos para prevenir y tratar enfermedades relacionadas con endotoxinas. | |
ATE335766T1 (de) | Antikörper gegen caspase-8, ihre herstellung und verwendung | |
ID27656A (id) | Turunan azabisikloheptana n-tersubstitusi, pembuatan dan penggunaannya | |
SE0100374D0 (sv) | Novel compositions of potassium channel openers and protein kinase c inhibitors and use thereof | |
ATE546157T1 (de) | Anti-pecam-therapie zur unterdrückung von metastasen | |
UA67058A (en) | Composition for treating periodontitis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
UEP | Publication of translation of european patent specification |
Ref document number: 1154793 Country of ref document: EP |